Amarantus Bioscience Holdings Inc. (OTCMKTS:AMBS) will be moving its headquarters to New York in an effort to raise more capital.
The biotech company develops therapeutic products to treat neurological, psychiatric, ophthalmological and degenerative disorders like Parkinson’s disease and Alzheimer’s disease.
The company recently relocated to New York from San Francisco.
CEO Gerald Commissiong told Proactive Investors on Tuesday that the company’s central nervous system asset is moving into Phase 2B trials later this year.
There will be 60 to 80 participants in the study before moving onto the third phase.
Amarantus has a market cap of US$2.97mln.